MedTrace Logo

Biparametric MRI in Prostate Cancer Screening: a Noninferior Randomized Controlled Study

NCT05025527 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2022-10-28

No results posted yet for this study

Summary

This is a single centre non-inferiority randomized controlled trial in comparison of the bpMRI between the traditional pathway in prostate cancer screening

Conditions

Interventions

DIAGNOSTIC_TEST

biparametric MRI (bpMRI)

Men go for the bpMRI for PCa (prostate cancer) screening, those who had a suspicious result will go for the next confirmation test

DIAGNOSTIC_TEST

Prostate cancer antigen (PSA)

Men go for the PSA test for PCa screening, those who had a suspicious result will go for the next confirmation test

Sponsors & Collaborators

  • Shanghai East Hospital

    lead OTHER

Principal Investigators

  • Haifeng Wang · Shanghai East Hospital,Tongji University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-12-01
Completion
2024-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05025527 on ClinicalTrials.gov